NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	systemic lupus erythematosus (SLE)
Date of first enrollment	30/08/2012
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LY2127399 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : LY2127399 240mg loading dose followed by 120 mg every 4 weeks and LY2127399 240mg loading dose followed by120 mg every 2 weeks for 52 weeks

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	antinuclear antibodies (ANA) positive patients age 18 or older with active SLE without active lupus nephritis or active central nervous system (CNS) involvement
Exclude criteria